New drug combo shows promise against aggressive breast cancer
NCT ID NCT01796197
First seen Feb 05, 2026 · Last updated May 12, 2026 · Updated 13 times
Summary
This study tested a three-drug combination (paclitaxel, trastuzumab, and pertuzumab) given before surgery to 23 people with a rare and aggressive type of breast cancer called inflammatory breast cancer. The goal was to see if the treatment could eliminate all signs of cancer in the breast and lymph nodes at the time of surgery. Participants also continued two of the drugs for a full year after surgery to help prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.